Skip to main content
. 2015 Aug 10;6(29):26971–26981. doi: 10.18632/oncotarget.4699

Figure 2. Comparison of the exosomal miR-21 levels in CSF (n = 70) or serum (n = 50) samples from low- and high-grade glioma patients with the non-glioma controls.

Figure 2

Meanwhile, A. Relative CSF miR-21 levels to GAPDH in low-grade (n = 35) and high-grade glioma groups (n = 35) versus in non-glioma patients (n = 25). B. Serum exosomal miR-21 in glioma patients (n = 50) versus non-glioma patients (n = 25). C. Comparison of CSF exosomal miR-21 level and D. Serum exosomal miR-21 between pre-surgery and post-surgery in two patients underwent the second operation due to tumor recurrence. *p < 0.05 and **p < 0.01.